Trial Profile
A Phase I/II Open Label Individual Dose Titration Trial of the Human Corticotropin- Releasing Factor (hCRF), Corticorelin Acetate Injection (Xerecept), to Determine the Tolerability of Xerecept in a Pediatric Population
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 03 Aug 2013
Price :
$35
*
At a glance
- Drugs Corticorelin (Primary)
- Indications Brain cancer
- Focus Adverse reactions
- 03 Aug 2013 New trial record